# A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

> **NCT05822908** · PHASE1,PHASE2 · RECRUITING · sponsor: **Vico Therapeutics B. V.** · enrollment: 68 (estimated)

## Conditions studied

- Spinocerebellar Ataxia Type 1
- Spinocerebellar Ataxia Type 3
- Huntington Disease

## Interventions

- **DRUG:** VO659

## Key facts

- **NCT ID:** NCT05822908
- **Lead sponsor:** Vico Therapeutics B. V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-14
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-10-15
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05822908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05822908, "A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05822908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*